Ananda Pharma

Ananda has just received MHRA and NHS Ethics approval for ENDOCAN-1, our Phase 2 clinical trial testing MRX1 CBD oral solution for endometriosis-associated pain. 190 million women live with this condition. Current treatments fail too many of them. We're changing that. Up to 100 women. 12 weeks. World-class researchers at the University of Edinburgh. Recruitment opens soon. Read the full announcement here: anandapharma.co.uk/announcements/… #Endometriosis #WomensHealth #ClinicalTrial #CBD #MRX1 #ENDOCAN #AnandaPharma #Biotech

Jack Morgan represented Ananda at JP Morgan Healthcare Week last month, and the week reinforced something critical, that real momentum is building in the sector. The full article is available here: anandapharma.co.uk/announcements/… Large pharma companies facing the patent cliff are actively seeking partnerships with focused biotech in areas of unmet need. What Jack heard repeatedly from investors and companies is that they want shorter timelines to market, robust clinical trial data, and measurable outcomes. This isn't news to us. This is exactly where Ananda has positioned itself. Jack met with investors, pharmaceutical partners, and service providers for our US expansion. He attended sessions on women's health and AI in healthcare. Most importantly, he left energized by the opportunities ahead. #Biotech #WomensHealth #HealthcareInnovation

In case you missed it...on 21 January, Ananda's CEO, Melissa Sturgess, and CCO, Jack Morgan, gave a presentation on Ananda and what the year ahead has in store for the Company. For those who were unable to join live, we’ve made the webinar recording and slides available via the link below. anandapharma.co.uk/announcements/… If you have any questions, please email ir@anandapharma.co.uk or leave a comment below. #ANA #presentation #update

We’ve shared our January 2026 Shareholder Update, outlining our transition to a private company, progress across our clinical trials, and priorities for the year ahead. Join our live shareholder webinar on Wednesday 21 January at 10am to hear directly from the team and ask questions. Register via: @543b7e45-f0ac-44ab-b9a9-60abe5c32b91" target="_blank" rel="nofollow noopener">events.teams.microsoft.com/event/0eb506e4… #ANA #MRX1 #clinicaltrials

Ananda Pharma welcomes the move as we advance MRX1 toward US Phase 2 trials. #Biotech #CBD #ClinicalResearch

President Trump signs Executive Order rescheduling cannabis from Schedule 1 to Schedule 3. A federal acknowledgement of medical use that supports faster research, FDA pathways, and access to capital.

Ananda Pharma has received combined ethics + MHRA approval for our Phase 2 trial of MRX1 in Chemotherapy-Induced Peripheral Neuropathy (CIPN). 20251110 CIPN ethics approval. CIPN has no approved treatments and affects 140k+ new UK patients yearly. Recruitment next. Updates to follow. Click here for the full announcement and to ask any questions: investors.anandapharma.co.uk/link/peg30e #ClinicalTrials #CIPN #Oncology #MRX1 #nihrprcs @SturgessMelissa

Endometriosis affects 1 in 10 women. Current treatments offer only temporary relief. At Ananda, we’re developing a CBD-based therapy that aims to target chronic pelvic pain and give women a better option. @SturgessMelissa #Endometriosis #CBD #Biotech

We’re featured in MJBizDaily: “How a woman-led biotech firm is advancing cannabis medicine.” CEO @SturgessMelissa will be at MJBizCon this December ahead of that, read about how pharma-grade cannabinoid research can change women’s health. Read more: mjbizdaily.com/ananda-pharma/ #MJBizCon #Biotech #Cannabinoids #Endometriosis #WomensHealth

⬇️⬇️⬇️

Finance Director Jeremy Sturgess-Smith toured the SGS facility in Deeside, where MRX1 is made. Holding a finished bottle was a surreal moment, bringing years of work at Ananda to life. Head over to our InvestorHub through the link in our bio to watch the video. #CBD #Biotech @SturgessMelissa

The AQSE is a UK-based market for growth companies, including Ananda Pharma Plc (ticker: ANA). If you are new to AQSE, check out the below👇🏻

Ananda Pharma is developing CBD-based treatments for endometriosis, targeting inflammation, lesion growth, and pain. In partnership with the University of Edinburgh, we’re advancing research to develop safe, evidence-based therapies for women. #Endometriosis #CBDResearch #AnandaPharma #PharmaceuticalInnovation #WomensHealth #ChronicPain @SturgessMelissa

New to Aquis? Here’s how to access AQSE stocks like Ananda Pharma (ANA): Check if your broker supports AQSE (e.g. HL, IG, II, AJ Bell) Search the ticker: ANA Don’t see it? Ask your broker to enable Aquis trading Learn More on AQSE: aquis.eu (Not investment advice) @SturgessMelissa

From oil and gas to biotech Chairman Charles Morgan shares how a market shock led him into genetic engineering, then biotech, and finally into regulated cannabinoid medicine at Ananda🎙️ #AnandaPharma #CBD #Biotech #CannabinoidMedicine #Leadership @SturgessMelissa

At the 8th Cannabinoid & Endocannabinoid Drug Development Summit, CEO @SturgessMelissa spoke on the growing momentum around cannabinoids in women’s health and how Ananda is advancing regulated CBD medicines💊. #AnandaPharma #CBD #Endometriosis #CannabinoidSummit

Never invested in Aquis before? Info below 👇🏼

We're incredibly excited for CEO @SturgessMelissa to present tomorrow at the 8th Cannabinoid & Endocannabinoid Summit in Boston, MA. She’ll share how Ananda is advancing regulated CBD medicines for women’s health💊. #AnandaPharma #CBD #Endometriosis #CannabinoidSummit

New to Aquis? Here’s how to access AQSE stocks like Ananda Pharma (ANA): Check if your broker supports AQSE (e.g. HL, IG, II, AJ Bell) Search the ticker: ANA Don’t see it? Ask your broker to enable Aquis trading Learn More on AQSE: aquis.eu (Not investment advice) @SturgessMelissa